



Better Health *for* a Better World®

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Founded nearly 60 years ago, Mylan today is one of the largest and most unconventional pharmaceutical companies in the world.

Extensive product portfolio: We have one of the industry's broadest and most diverse portfolios, with more than 7,500 marketed products around the world that include prescription generic and brand name medicines, and over-the-counter (OTC) offerings. Our healthcare services help patients access products, adhere to medication regimes and help promote better health outcomes.

Expansive commercial footprint: Our team of approximately 7,000 sales and marketing professionals around the world promote awareness of Mylan's broad and diverse portfolio of generic, branded, branded generic and OTC products in more than 165 countries and territories.

World-class supply chain: Depending on the market, our products are distributed through retail channels, by healthcare professionals or in institutional settings. Our proven supply chain helps ensure that our medicines are available whenever and wherever needed – from large cities to rural outposts.

Substantial research and development capabilities: We have a strong track record of developing new products, particularly complex and difficult-to-formulate medicines. Between 2013-2017, we have invested more than \$3 billion in R&D. As a result, we have a robust pipeline, including products for which demand is growing rapidly, such as more-affordable versions of insulin analogs, biologics and respiratory therapies.

Powerful, high quality manufacturing platform: Our 47 plants around the world manufacture tens of billions of doses of medicine annually, and our sites aim to adhere to stringent quality standards, regardless of location. Further, our platform is vertically integrated – meaning we produce active pharmaceutical ingredients and finished products – allowing us to rigorously manage per-dosage costs.

Champions for better health: Our most valuable asset is our global workforce, each member of which is a passionate supporter of our cause to deliver better health for a better world. Led by executives of long tenure and deep industry experience, our entire team prides itself on being relentless, committed, passionate and unconventional.

GLOBAL FAST FACTS

More than 7,500 marketed products

Serve more than 165 countries and territories

Global workforce of approximately 35,000

Annual production capacity of more than 75 billion oral solid doses, approximately 1.3 billion complex-product doses and approximately 500 million injectable units

More than 1,000 projects in the pipeline across the regions; approximately 1,800 products pending approval.

More than 3,000 scientists and regulatory affairs experts; multiple state-of-the-art R&D centers

More than \$3B of cumulative R&D spend from 2013-2017

More than 40% of the nearly 21 million HIV+ patients being treated today – and 60% of the world's HIV+ children – depend on one of our products.

2017 revenue: \$11.9 billion

Ticker: MYL (NASDAQ)

OUR MISSION

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:

- Innovate to satisfy unmet needs;
- Make reliability and service excellence a habit;
- Do what's right, not what's easy; and
- Impact the future through passionate global leadership.

Mylan in the United States

While Mylan may not be a household name yet, our products can likely be found in most American homes. Mylan is the second largest provider of prescription medicine in the U.S.

Extensive product portfolio: We offer more than 650 different products, spanning virtually every key therapeutic area.

Significant savings: We have a proven track record of delivering savings to the nation's healthcare system. With generic drugs making up 90% of prescriptions dispensed, yet only 23% of total drug spending, Mylan plays an important role in expanding patient access to high quality medicine and keeping healthcare costs in check. We look forward to driving even more savings as we bring to market more affordable versions of insulin analogs, biologics and respiratory therapies.

Robust pipeline: We have a robust pipeline, with approximately 200 generic drug applications pending approval by the U.S. Food and Drug Administration (FDA).

Passionate policy leadership: Our deep roots in shaping public policy continue to help break down barriers to access. We played a leading role in championing the Food and Drug Administration Safety and Innovation Act, passed in 2012, which requires foreign manufacturers to be held to the same quality standards as U.S. drug manufacturers. We also led the way to secure funding for the agency, through the Generic Drug User Fee Act, to hold all facilities to these standards, regardless of location.

To learn more visit: Mylan.com



#2 provider of prescription medicines

Workforce of
~5,500
with ~40% in STEM fields

In the last 5 years,
Mylan launched more generics than any other company

The majority of doses we sell in America **are made in America***

*Manufactured from domestic and international components.

Founded in 1961
in **White Sulphur Springs, WV**

One of the industry's broadest pipelines with **>200 applications pending approval**

With employees in **nearly every state**, Mylan has operations, R&D, commercial or administrative offices in **7 states, Washington D.C. and Puerto Rico.**



Government Relations:

+1.202.507.5325

Government.Relations@mylan.com

Investor Relations:

+1.724.514.1813

InvestorRelations@mylan.com

Media Relations:

+1.724.514.1968

Communications@mylan.com

Stay Connected:

Mylan.com

[LinkedIn](#)

[YouTube](#)



@MylanNews
@MylanCareers

 **Mylan**

Better Health
for a Better World®